New Drug Plus Pertuzumab for HER2-Positive Breast Cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called SHR-A1811 combined with pertuzumab (Perjeta) before surgery for patients with HER2-positive breast cancer that has not spread beyond the breast and nearby lymph nodes. The goal is to shrink the cancer before surgery and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- Your breast cancer is stage II or III (not spread to distant organs) and confirmed HER2-positive
- You have not received any chemotherapy, radiation, or targeted drugs for this cancer yet
- Your heart, liver, and kidney function are adequate (measured by blood tests and heart imaging)
- You are willing to use effective birth control during treatment and for 8 weeks after if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
This trial tests a new combination of two targeted drugs (Trastuzumab Rezetecan and Pertuzumab) given before surgery for HER2-positive breast cancer. The goal is to see if this approach shrinks tumors more effectively.
This trial tests a new combination of drugs (DV plus pertuzumab, with or without toripalimab) given before surgery for HER2-positive breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This trial tests a new drug called SHR-A1811 combined with pertuzumab given before surgery to shrink tumors in people with early or locally advanced, hormone receptor-positive and HER2-positive breast cancer. It is designed to see if this combination can help reduce tumor size better.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.